2023
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Tsuboi M, Herbst R, John T, Kato T, Majem M, Grohé C, Wang J, Goldman J, Lu S, Su W, de Marinis F, Shepherd F, Lee K, Le N, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu Y. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. New England Journal Of Medicine 2023, 389: 137-147. PMID: 37272535, DOI: 10.1056/nejmoa2304594.Peer-Reviewed Original ResearchConceptsDisease-free survivalOverall survivalIIIA diseaseStage IBAdjuvant osimertinibPlacebo groupOsimertinib groupNew serious adverse eventsSignificant overall survival benefitStage IILonger disease-free survivalEnd pointData cutoff datePrevious adjuvant chemotherapyDouble-blind trialOverall survival benefitPrimary end pointSecondary end pointsSerious adverse eventsCell lung cancerCoronavirus disease 2019Epidermal growth factor receptorADAURA trialAdjuvant chemotherapyEligible patientsEGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).
Nassar A, Adib E, Feng J, Aredo J, Parikh K, Harris J, Velazquez Manana A, Ragavan M, Lin J, Piotrowska Z, Fitzgerald B, Grohé C, Sankar K, Neal J, Wakelee H, Shepherd F, Herbst R, Naqash A, Goldberg S, Kim S. EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC). Journal Of Clinical Oncology 2023, 41: 8567-8567. DOI: 10.1200/jco.2023.41.16_suppl.8567.Peer-Reviewed Original ResearchEGFR tyrosine kinase inhibitorsDisease-free survivalTyrosine kinase inhibitorsTreatment-related adverse eventsConcurrent chemoradiationOverall survivalStage IIILonger disease-free survivalMulti-institutional retrospective analysisDefinitive radiation therapyPD-L1 expressionPD-L1 statusDefinitive concurrent chemoradiationEGFR-TKI therapyPlatinum-based chemotherapyCell lung cancerEGFR-mutant NSCLCGy of radiationAdjuvant osimertinibCTCAE 5.0PACIFIC trialAdvanced NSCLCConcurrent chemotherapyBaseline characteristicsMedian duration
2015
Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials’ experience
Ramirez A, Wages N, Hu Y, Smolkin M, Slingluff C. Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials’ experience. Cancer Immunology, Immunotherapy 2015, 64: 1531-1539. PMID: 26392296, PMCID: PMC4644444, DOI: 10.1007/s00262-015-1758-5.Peer-Reviewed Original ResearchConceptsDisease-free survivalT cell responsesOverall survivalImmune responseOlder patientsCancer vaccinesClinical outcomesResected stage IIB-IV melanomaCD8+ T cell responsesStage IIB-IV melanomaLonger disease-free survivalImpact of patient ageMelanoma-associated peptidesCancer vaccine trialsClinical trial experienceIncidence of IRCumulative incidence rateKaplan-Meier estimatesClass I MHCMelanoma vaccineMenopausal statusPatient ageSurvival outcomesStratify patientsFemale patients
2009
Ovarian Preservation and Staging in Reproductive-Age Endometrial Cancer Patients
Richter C, Qian B, Martel M, Yu H, Azodi M, Rutherford T, Schwartz P. Ovarian Preservation and Staging in Reproductive-Age Endometrial Cancer Patients. Obstetrical & Gynecological Survey 2009, 64: 726-727. DOI: 10.1097/01.ogx.0000361368.51892.57.Peer-Reviewed Original ResearchDisease-free survivalLonger disease-free survivalSurgical stagingEndometrial cancerOvarian preservationClinical stagingPremenopausal womenEndometrial carcinomaEarly-stage low-grade endometrial cancerEarly-stage endometrial cancerEarly-stage endometrial carcinomaLow-grade endometrial cancerYoung womenLong-term adverse effectsAggressive surgical stagingGrade 1 diseaseStage endometrial cancerEndometrial cancer patientsStage 1 diseaseTotal abdominal hysterectomyEarly-stage patientsLonger overall survivalLarge university hospitalQuality of lifeParaaortic lymphadenectomyOvarian preservation and staging in reproductive-age endometrial cancer patients
Richter CE, Qian B, Martel M, Yu H, Azodi M, Rutherford TJ, Schwartz PE. Ovarian preservation and staging in reproductive-age endometrial cancer patients. Gynecologic Oncology 2009, 114: 99-104. PMID: 19410280, DOI: 10.1016/j.ygyno.2009.03.032.Peer-Reviewed Original ResearchConceptsDisease-free survivalLonger disease-free survivalYale-New Haven HospitalEndometrial cancer patientsOvarian preservationSurgical stagingOverall survivalEndometrial cancerCancer patientsEarly-stage low-grade endometrial cancerStage IYoung endometrial cancer patientsBetter disease-free survivalLow-grade endometrial cancerGrade 1 diseaseRetrospective chart reviewLonger overall survivalChart reviewYounger patientsClinical stagingSurgical treatmentEndometrial carcinomaGynecologic pathologistsRisk factorsAge 45
1995
Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma
Levesque M, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis E. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995, 75: 1327-1338. PMID: 7882283, DOI: 10.1002/1097-0142(19950315)75:6<1327::aid-cncr2820750615>3.0.co;2-p.Peer-Reviewed Original ResearchConceptsEpithelial ovarian carcinomaOvarian carcinomaMutant p53 proteinResidual tumorHistologic gradeOvarian cancerP53 proteinCancer relapseMutant p53 protein overexpressionLonger disease-free survivalKaplan-Meier survival curvesPostsurgical residual tumorDisease-free survivalEarly-stage diseaseSubset of patientsLow histologic gradeMutant p53 protein accumulationAdvanced-stage cancerDifferent clinical stagesP53-negative tumorsP53-positive tumorsP53 protein overexpressionPoor patient outcomesAnti-p53 antibodiesP53 protein accumulation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply